Skip to main content

View full-text article in PMC

letter

. 2021 Apr 20;99(6):1489–1490. doi: 10.1016/j.kint.2021.03.032

Table 1.

Frequency of SARS-CoV-2–reactive T cells in dialysis and nondialysis patients

Group, %	CD4⁺CD154⁺CD137⁺	CD4⁺CD154⁺CD137⁺
Group, %	CD4⁺CD154⁺CD137⁺	+Granzyme B⁺	+IFN-γ⁺	+IL-2⁺	+TNF⁺
Dialysis	0.7745 (0.057–1.57)	0.02029 (0–0.134)	0.1538 (0.017–0.437)	0.42 (0.054–0.651)	0.282 (0.02–0.588)
Nondialysis	0.237 (0.031–0.734)	0 (0–0.025)	0.0255 (0–0.195)	0.1165 (0.023–0.3)	0.0705 (0.012–0.223)

Group, %	CD8⁺CD137⁺	CD8⁺CD137⁺
Group, %	CD8⁺CD137⁺	+Granzyme B⁺	+IFN-γ⁺	+IL-2⁺	+TNF⁺
Dialysis	0.355 (0.187–1.21)	0.2795 (0.08–0.61)	0.0225 (0–0.1665)	0.0225 (0–0.096)	0.085 (0–0.15)
Nondialysis	0.1325 (0–0.33)	0.0205 (0–0.107)	0 (0–0.06)	0 (0–0.018)	0 (0–0.045)

IFN-γ, interferon-γ; IL-2, interleukin-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF, tumor necrosis factor.

Frequency of SARS-CoV-2–reactive CD4⁺ or CD8⁺ T cells among all CD4⁺ or CD8⁺ T cells. Data are given as median (95% confidence interval).